Perospirone is a new generation antipsychotic: Evidence from a positron emission tomography study of serotonin 2 and D2 receptor occupancy in the living human brain [2]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 5, 2006, Pages 531-533

  Sekine, Yoshimoto ^a   Ouchi, Yasuomi ^b   Takei, Nori ^a,c   Yoshikawa, Etsuji ^d   Okada, Hiroyuki ^d   Minabe, Yoshio ^a   Nakamura, Kazuhiko ^a   Suzuki, Katsuaki ^a   Iwata, Yasuhide ^a   Tsuchiya, Kenji J ^a   Sugihara, Genichi ^a   Mori, Norio ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU MEDICAL CENTER   (Japan)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d HAMAMATSU PHOTONICS K K   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; HYDROXYPEROSPIRONE; ISOINDOLE DERIVATIVE; PEROSPIRONE; SEROTONIN 2 RECEPTOR; UNCLASSIFIED DRUG;

ADULT; BINDING AFFINITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RECEPTOR BINDING; FRONTAL CORTEX; HUMAN; LETTER; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RECEPTOR OCCUPANCY;

ADULT; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; BRAIN; HUMANS; INDOLES; ISOINDOLES; MALE; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN, 5-HT2; REFERENCE VALUES; SPIPERONE; THIAZOLES;

EID: 33748746751     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000236659.93415.4a     Document Type: Letter

References (13)

1. Onrust SV, McClellan K. Perospirone. CNS Drugs. 2001;15:329-337.
2. Japan Pharmacists Education Center. New Drug Approval Package No. 61: Perospirone. (in Japanese); 2000.
3. Yasui-Furukori N, Furukori H, Nakagami T, et al. Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004;26:361-365.
4. Nyberg S, Farde L, Eriksson L, et al. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology. 1993;110:265-272.
5. Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999;156:869-875.
6. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544.
7. Sekine Y, Ouchi Y, Takei N, et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry. 2006;63:90-100.
8. Yasui-Furukori N, Inoue Y, Tateishi T. Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;789:239-245.
9. Remington G, Kapur S, Zipursky R. The relationship between risperidone plasma levels and dopamine D2 occupancy: a positron emission tomographic study. J Clin Psychopharmacol. 1998;18:82-83.
10. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand (Suppl). 1970;212:11-19.
11. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
12. Meltzer HY. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol. 1995;15(suppl 1):2S-3S.
13. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286-293.